Literature DB >> 25901433

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Hans C Hasselbalch, Mads E Bjørn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25901433     DOI： 10.1056/NEJMc1502524

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.

Authors:  Xiao Jun Huang; Kaiyan Liu; David Ritchie; Borje Andersson; Jin Lu; Jian Hou; Adolfo de la Fuente Burguera; JianXiang Wang; Allen Yeoh; Chenhua Yan; Daobin Zhou; Daryl Tan; Dong Wook Kim; Depei Wu; Elizabeth Shpall; Stephen Kornblau; Sattava Neelapu; Suradej Hongeng; Jianyong Li; Jiong Hu; Lian Sheng Zhang; Michael Wang; Pankaj Malhotra; Qian Jiang; Yazhen Qin; Raymond Wong; Richard Champlin; Frederick Hagemeister; Jason Westin; Swaminathan Iyer; Vikram Mathews; Yu Wang; Yu Hu; Zhijian Xiao; Zonghong Shao; Robert Z Orlowski; Chor Sang Chim; Stephen Mulligan; Miguel Sanz; Keiya Ozawa; Simrit Parmar; Surapol Issaragrisil
Journal:  Oncotarget       Date:  2017-06-20

2.  Xanthatin inhibits STAT3 and NF-κB signalling by covalently binding to JAK and IKK kinases.

Authors:  Man Liu; Cheng-Qian Xiao; Ming-Wei Sun; Min-Jia Tan; Li-Hong Hu; Qiang Yu
Journal:  J Cell Mol Med       Date:  2019-04-16       Impact factor: 5.310

3.  CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of JAK2 V617F Somatic Mutation in Myeloproliferative Neoplasms.

Authors:  Miaomiao Chen; Chunhua Zhang; Zhiqing Hu; Zhuo Li; Menglin Li; Lingqian Wu; Miaojin Zhou; Desheng Liang
Journal:  Biosensors (Basel)       Date:  2021-07-24

Review 4.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.